What is Nutrisense?
Nutrisense offers a Continuous Glucose Monitoring (CGM) program designed to provide users with detailed insights into how their diet, exercise, lifestyle, and sleep patterns impact their blood glucose levels. The program emphasizes accountability through regular CGM sensor scans and provides support from registered dietitians to help individuals achieve their personal health objectives. This approach positions Nutrisense as a key player in personalized health management and preventative wellness.
How much funding has Nutrisense raised?
Nutrisense has raised a total of $25.1M across 2 funding rounds:
Debt
$73K
Series A
$25M
Debt (2021): $73K with participation from PPP
Series A (2022): $25M led by 1315 Capital
Key Investors in Nutrisense
1315 Capital
1315 Capital is a healthcare-focused investment firm that specializes in commercial-stage healthcare companies, including healthcare services, pharma/medtech products, outsourcing, and health & wellness. The firm aims to support exceptional teams and scalable businesses that positively impact patients and the healthcare system.
PPP
Public-Private Partnership
What's next for Nutrisense?
The substantial enterprise-level funding and recent strategic investment indicate a strong growth trajectory for Nutrisense. This capital infusion is likely to fuel further product development, expansion of services, and broader market penetration. The company is poised to enhance its CGM technology and support systems, potentially solidifying its position as a leader in the digital health and wellness space, helping more individuals gain control over their metabolic health.
See full Nutrisense company page
